News Focus
News Focus
icon url

boi568

10/20/23 3:15 PM

#436114 RE: Bourbon_on_my_cornflakes #436111

Missling just does not conduct himself like the usual CEO. He doesn't raise money the same way, he doesn't spend the same way, he uses late stage trials as research instruments more than anyone else, he doesn't communicate the same way, he doesn't seem to care much for deadlines, and he certainly doesn't try to manage the stock price the same way. He's a different animal.

So complaining that he isn't meeting the usual expectations for the usual CEOs is kind of silly. We should not make the usual inferences when he is not the usual actor.
icon url

Steady_T

10/20/23 11:48 PM

#436213 RE: Bourbon_on_my_cornflakes #436111

As far as the AD NDA, Anavex has said that Rett will come first. So, no AD NDA until Rett NDA is filed and far enough into the pipeline that AD won't get approved first.

As for the Rett NDA, the company feels the pressure to file just like we do. Rett approval will generate a significant cash flow and enable the company to pursue additional trials.

I talked to IR today and couldn't get any info on where the company is on filing the Rett NDA.